LBTYA News Today: Stay Updated with the Latest Liberty Global plc News in Real Time
Find LBTYA news now at Meyka AI. Stay informed with the latest{" "} Liberty Global plc stocks updates, including price news, market analysis, and expert insights.
SK Hynix Seals Multi-Year AI Deal With Nvidia, June 08
SK Hynix signs multi-year partnership with Nvidia to develop advanced memory for AI data centers. Deal secures supply as memory demand surges.
Japan’s Trade Deficit Shrinks as Yen Weakens, June 09
Japan’s April trade deficit shrinks to 20.3 billion yen as primary income reaches 4.21 trillion yen. Yen hovers near 160 amid intervention.
Tech Rout Triggers Global Selloff as Iran-Israel Tensions Spike, June 09
Tech stocks rebound as Iran-Israel tensions ease. South Korea’s Kospi fell 8.3%, Nasdaq rose 1.2%. Oil prices spike on geopolitical risks.
Gold Falls 1.2% to ₹1,53,620 Per 10g as US Jobs Data Stokes Rate Hike Fears, June 09
Gold prices in India fell 1.2% to ₹1,53,620 per 10g on June 8, 2026, amid strong US jobs data and rising Treasury yields.
Nikkei 225 Plunges 3.85% to 64,024.6 on Tech Rout, June 08
Nikkei 225 drops 3.85% to 64,024.6 on June 8 as chip stocks fall, U.S. rate hike fears mount, and Middle East tensions spike oil prices.
Putin Offers Su-57 Fighter Technology to India, June 08
Putin offers India full access to Su-57 fighter technology, joint production, and technology transfer to strengthen defense ties.
Mexican Peso Weakens 0.572% as Dollar Strength Persists, June 08
Mexican peso drops 0.572% against US dollar on June 5, 2026. Largest 24-hour decline shows currency weakness amid broader forex market volatility.
STI Falls 1.7% to 4,963.67 on Tech Rout and Middle East Tensions, June 08
Singapore’s STI index fell 1.7% to 4,963.67 on June 8 amid global tech selloff and Middle East tensions. Semiconductors led losses.
Eli Lilly Stock (LLY) Jumps 4% to $1,131.42 USD as Retatrutide Cuts Sleep Apnea by 60% in Phase 3 Trial
Eli Lilly stock gained approximately 4 percent and climbed to $1,131.42 USD after the company announced promising Phase 3 clinical trial results for Retatrutide. The experimental drug demonstrated a remarkable ability to reduce obstructive sleep apnea severity by nearly 60 percent, generating excitement among investors and healthcare professionals. The announcement strengthened confidence in Eli Lilly’s…